Nov 21, 2014 at 18:02 | Source: CNBC-TV18
Anand Tandon says, one should look at stocks where there is still value. "If one looks at market as a whole there are still sectors available that are reasonably cheap like IT which has been ignored because growth rate is presumed to be slower than other cyclicals," he adds.
Nov 21, 2014 at 13:47 | Source: Moneycontrol.com
The multinational pharmaceutical company with current market capitalisation of nearly Rs 51,000 crore has a portfolio that includes 2000 products in 65 therapeutic categories with one quality standard globally.
Nov 21, 2014 at 11:33 | Source: Moneycontrol.com
The brokerage says Cipla aims to grow its sales from USD 1.6 billion to USD 5 billion by FY20 (21 percent compounded annual growth rate - CAGR).
Nov 21, 2014 at 10:04 | Source: Moneycontrol.com
Cipla surged 2.67 percent as brokerage house Bank of America Merrill Lynch said Cipla will triple its sales by FY20.
Nov 21, 2014 at 10:00 | Source: CNBC-TV18
Ajay Srivastava is bullish on cement, tyre, IT and pharma space. Among stocks, Srivastava likes JK Lakshmi, Shree cement, Sun Pharma, Lupin, Tech Mahindra, Infosys and Oracle.
Nov 21, 2014 at 08:51 | Source: CNBC-TV18
Vishal Kshatriya of Edelweiss recommends buying Hexaware Technologies for a target price of Rs 235-240 and Cipla with a target of Rs 640.
Nov 20, 2014 at 13:44 | Source: PTI
As per the agreement, Serum Institute of India (SII) will develop and manufacture paediatric vaccines and Cipla will seek European Medicines Agency approval and market the products in Europe, the company said in a statement.
Nov 20, 2014 at 13:31 | Source: CNBC-TV18
Mithil Pradhan of Violet Arc Global Managers recommends going long in Cipla with a target of Rs 650-670.
Nov 20, 2014 at 12:48 | Source: CNBC-TV18
Watch the interview of Mithil Pradhan of Violet Arc Global Managers with Sonia Shenoy and Anuj Singhal on CNBC-TV18, in which he shared his readings and outlook on market and specific stocks.
Nov 20, 2014 at 12:25 | Source: Moneycontrol.com
KRChoksey is bullish on Cipla and has recommended buy rating on the stock with a target price of Rs 636 in its November 14, 2014 research report.